Search results for: PSA
Error loading info... Pleas try again later.
#33098158 2020/10/23 To Up
Negative first follow-up prostate biopsy on active surveillance is associated with decreased risk of upgrading, suspicion of progression and converting to active treatment.To determine the risk of disease progression and conversion to active treatment following a negative biopsy while on AS for PCa.
Sohail Singh, Preeti Sandhu, Kerri Beckmann, Aida Santaolalla, Kamal Dewan, Sharon Clovis, Jonah Rusere, Grace Zisengwe, Benjamin Challacombe, Christian Brown, Paul Cathcart, Rick Popert, Prokar Dasgupta, Mieke Van Hemelrijck, Oussama Elhage
1864 related Products with: Negative first follow-up prostate biopsy on active surveillance is associated with decreased risk of upgrading, suspicion of progression and converting to active treatment.5 ug1 kit(96 Wells)1 mg25 units5 ug5 ug0.1mg0.1ml (1.3mg/ml)
#33097960 2020/10/23 To Up
PsART-ID inception cohort: clinical characteristics, treatment choices and outcomes of patients with psoriatic arthritis.Our aim is to understand clinical characteristics, real-life treatment strategies, outcomes of early PsA patients and determine the differences between the inception and established PsA cohorts.
Gizem Ayan, Sibel Zehra Aydin, Gezmis Kimyon, Cem Ozisler, Ilaria Tinazzi, Atalay Dogru, Ahmet Omma, Levent Kilic, Sema Yılmaz, Orhan Kucuksahin, Emel Gönüllü, Fatih Yıldız, Meryem Can, Ayşe Balkarlı, Dilek Solmaz, Ediz Dalkılıc, Ozun Bayindir, Gözde Yıldırım Çetin, Serpil Ergulu Esmen, Emine Duygu Ersozlu, Mehmet Tuncay Duruoz, Lütfi Akyol, Adem Kucuk, Cemal Bes, Muhammet Cınar, Abdulsamet Erden, Rıdvan Mercan, Sibel Bakirci, Timucin Kasifoglu, Veli Yazısız, Umut Kalyoncu
1231 related Products with: PsART-ID inception cohort: clinical characteristics, treatment choices and outcomes of patients with psoriatic arthritis.5 GML
No related Items
#33097948 2020/10/23 To Up
Treatment of psoriatic arthritis with biologic and targeted synthetic DMARDs: British Society for Rheumatology guideline scope.The aim of this guideline is to provide an update on evidence-based recommendations for treatment of adult patients with PsA. The previous BSR guidelines for PsA were published in 2012 and since that time, there have been many new advanced therapies licensed for PsA. This update will provide practical guidance for clinicians on the optimal selection of advanced therapies taking into account different domains of PsA (arthritis, enthesitis, dactylitis, axial disease and psoriasis) and key associated comorbidities. It will also update guidance on treatment strategy including the use of a treat-to-target approach. The guideline will be developed using the methods and processes outlined in Creating Clinical Guidelines: Our Protocol. (1) This development process to produce guidance, advice and recommendations for practice has National Institute for Health and Care Excellence (NICE) accreditation.
William Tillett, Alexander Allen, Laura Tucker, David Chandler, Coziana Ciurtin, Charlotte Davis, Andrew Dick, Amy Foulkes, Nicola Gullick, Philip Helliwell, Deepak Jadon, Gareth Jones, Stuart Kyle, Vishnu Madhok, Neil McHugh, Andrew Parkinson, Tim Raine, Stefan Siebert, Catherine Smith, Laura C Coates
2260 related Products with: Treatment of psoriatic arthritis with biologic and targeted synthetic DMARDs: British Society for Rheumatology guideline scope.10 25 MG100ul10 ml100 µg 125 ml 25 mg1 mg1 ml250 mg
#33096129 2020/10/20 To Up
Trends in Mortality and Cause-specific Mortality among patients with Psoriasis and Psoriatic Arthritis in Ontario, Canada.There is limited information about mortality rates among patients with psoriasis and psoriatic arthritis (PsA) in North America and their change over the past two decades.
Keith Colaco, Jessica Widdifield, Jin Luo, Cheryl F Rosen, Raed Alhusayen, J Michael Paterson, Willemina Campbell, Karen Tu, Sasha Bernatsky, Dafna D Gladman, Lihi Eder
2614 related Products with: Trends in Mortality and Cause-specific Mortality among patients with Psoriasis and Psoriatic Arthritis in Ontario, Canada.4 Membranes/Box2 Pieces/Box4 Membranes/Box4 Arrays/Slide10mg4 Arrays/Slide2 Pieces/Box2 Pieces/Box4 Membranes/Box2 Pieces/Box4 Arrays/Slide96tests
No related Items
#33095670 2020/10/23 To Up
Magnetic resonance image-guided adaptive stereotactic body radiotherapy for prostate cancer: preliminary results.Using moderate or ultra hypofractionation, which is also known as stereotactic body radiotherapy (SBRT) for treatment of localized prostate cancer patients has been increased. We present our preliminary results on the clinical utilization of magnetic resonance image-guided adaptive radiotherapy (MRgRT) for prostate cancer patients with the workflow, dosimetric parameters, toxicities and prostate specific antigen (PSA) response.
Gamze Ugurluer, Banu Atalar, Teuta Zoto Mustafayev, Gorkem Gungor, Gokhan Aydin, Meric Sengoz, Ufuk Abacioglu, Ali Riza Kural, Mustafa Bilal Tuna, Enis Ozyar
1028 related Products with: Magnetic resonance image-guided adaptive stereotactic body radiotherapy for prostate cancer: preliminary results.
#33094683 // To Up
Deletion of NKX3.1 via CRISPR/Cas9 Induces Prostatic Intraepithelial Neoplasia in C57BL/6 Mice.Several techniques have been employed for deletion of the NKX3.1 gene, resulting in developmental defects of the prostate, including alterations in ductal branching morphogenesis and prostatic secretions as well as epithelial hyperplasia and dysplasia. To investigate whether the CRISPR/Cas9-mediated technique can be applied to study prostate carcinogenesis through exon I deletion of NKX3.1 gene, alterations in the prostatic intraepithelial neoplasia (PIN) and their regulatory mechanism were observed in the prostate of NKX3.1 knockout (KO) mice produced by the CRISPR/Cas9-mediated NKX3.1 mutant gene, at the ages of 16 and 24 weeks. The weight of dorsal-lateral prostate (DLP) and anterior prostate (AP) were observed to be increased in only the 24 weeks KO mice, although morphogenesis was constant in all groups. Obvious PIN 1 and 2 lesions were frequently detected in prostate of the 24 weeks KO mice, as compared with the same age wild type (WT) mice. Ki67, a key indicator for PIN, was densely stained in the epithelium of prostate in the 24 weeks KO mice, while the expression of p53 protein was suppressed in the same group. Also, both the 16 and 24 weeks KO mice reveal inhibition of the PI3K/AKT/mTOR pathway in the prostate. However, prostate specific antigen (PSA) levels and Bax/Bcl-2 expressions were decreased in the prostate of 16 weeks KO mice, and were increased in only the 24 weeks KO mice. Taken together, the results of the present study provide additional evidence that CRISPR/Cas9-mediated exon 1 deletion of the NKX3.1 gene successfully induces PIN lesions, along with significant alterations of Ki67 expression, EGFR signaling pathway, and cancer-regulated proteins.
Jin Ju Park, Ji Eun Kim, Yoon Jeon, Mi Rim Lee, Jun Young Choi, Bo Ram Song, Ji Won Park, Mi Ju Kang, Hyeon Jun Choi, Su Ji Bae, Ho Lee, Byeong Cheol Kang, Dae Youn Hwang
1097 related Products with: Deletion of NKX3.1 via CRISPR/Cas9 Induces Prostatic Intraepithelial Neoplasia in C57BL/6 Mice.100mg100ug Lyophilized100ug Lyophilized100ug Lyophilized 100ul500 MG100ug Lyophilized 100ul100ug
Error loading info... Pleas try again later.
#33092646 2020/10/22 To Up
Weight loss is associated with sustained improvement of disease activity and cardiovascular risk factors in patients with psoriatic arthritis and obesity: a prospective intervention study with two years of follow-up.Obesity is overrepresented in patients with psoriatic arthritis (PsA) and associated with increased disease activity. We have previously shown in 41 patients with PsA (Caspar criteria) and obesity (body mass index; BMI ≥33 kg/m) that weight loss treatment with Very Low Energy Liquid Diet (VLED), 640 kcal/day during 12-16 weeks, followed by a structured reintroduction of an energy restricted diet resulted in a median weight loss of 18.6% and concomitantly a significant improvement of the disease activity in joints, entheses and skin. The objectives of this follow-up were to study the effects of the weight loss treatment on disease activity in longer term (12 and 24 months) and to study the effects on cardiovascular risk factors.
Eva Klingberg, Sofia Björkman, Björn Eliasson, Ingrid Larsson, Annelie Bilberg
2993 related Products with: Weight loss is associated with sustained improvement of disease activity and cardiovascular risk factors in patients with psoriatic arthritis and obesity: a prospective intervention study with two years of follow-up.0.1ml (1mg/ml)100 μg0.1ml100ug Lyophilized100ug Lyophilized100ug Lyophilized25 mg100 ul100ug Lyophilized100ug Lyophilized100ug Lyophilized
#33090770 2020/10/22 To Up
Powerful Chemiluminescence Probe for Rapid Detection of Prostate Specific Antigen Proteolytic Activity: Forensic Identification of Human Semen.The prostate specific antigen (PSA), a serine protease with chymotrypsin-like activity, is predominantly expressed in the prostate and is considered as the most common marker in use to identify and follow the progress of prostate cancer. In addition, it is also now accepted as a marker for detecting semen in criminal cases. Here, we describe the design, synthesis, and evaluation of the first chemiluminescence probe for detection of PSA enzymatic activity. The probe activation mechanism is based on a catalytic cleavage of a specific peptidyl substrate, followed by a release of a phenoxy-dioxetane luminophore, that then undergoes efficient chemiexcitation to emit a green photon. The probe exhibits a significant turn-on response upon reaction with PSA and produces strong light emission signal with an extremely high signal-to-noise ratio. Comparison of the chemiluminescence probe with an analogous fluorescence probe showed superior detection capability in terms of response time and sensitivity. In addition, the probe was able to efficiently detect and image human semen traces on fabric, even after 3 days from sample preparation. The advantageous sensitivity and simplicity of a chemiluminescence assay to detect seminal fluid was effectively demonstrated by on-site measurements using a small portable luminometer. It is expected that the new chemiluminescence probe would be broadly useful for numerous applications in which PSA detection or imaging is required.
Sara Gutkin, Ori Green, Gil Raviv, Doron Shabat, Orith Portnoy
2175 related Products with: Powerful Chemiluminescence Probe for Rapid Detection of Prostate Specific Antigen Proteolytic Activity: Forensic Identification of Human Semen.0.05 mg1 kit(96 Wells) 25 ml Ready-to-use 6 ml Ready-to-use 100 TESTS0.1 mg 6 ml Ready-to-use 2 ml Ready-to-use 25 µg0.2 mg0.1 mg96 tests
Voortstraat 49, 1910 Kampenhout BELGIUM
Tel 0032 16 58 90 45 Fax 0032 16 50 90 45
9, rue Lagrange, 75005 Paris
Tel 01 43 25 01 50 Fax 01 43 25 01 60
52062 Aachen Deutschland
Tel 0241 40 08 90 86 Fax 0241 55 91 05 36
Howard Frank Turnberry House
1404-1410 High Road
Whetstone London N20 9BH
Tel 020 3393 8531 Fax 020 8445 9411
Schweiz Züri +41435006251
Česká republika Praha +420246019719
Ireland Dublin +35316526556
Norge Oslo +4721031366
Finland Helsset +358942419041
Sverige Stockholm +46852503438
Ελλάς Αθήνα +302111768494
Magyarország Budapest +3619980547
GENTAUR Poland Sp. z o.o.
ul. Grunwaldzka 88/A m.2
81-771 Sopot, Poland
Tel 058 710 33 44
Fax 058 710 33 48
GENTAUR Nederland BV
5521 DG Eersel Nederland
Tel 0208-080893 Fax 0497-517897
Piazza Giacomo Matteotti, 6, 24122 Bergamo
Tel 02 36 00 65 93 Fax 02 36 00 65 94
53 Iskar Str. 1191 Kokalyane, Sofia